Amphora Discovery has sold some of its technology to Caliper Life Sciences for use in cell-based screening assays, the companies said Thursday.

Terms were not disclosed other than Caliper will compensate Amphora with cash. Products and royalties.

Amphora already used microfluidic technology from Caliper.

“Amphora will transfer to Caliper its proprietary cell culture techniques, as well as various hardware and software upgrades that Amphora has implemented on Caliper’s proprietary microfluidic screening system,” Amphora said in a statement.